Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

iTeos Therapeutics Inc. (Nasdaq: ITOS)

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). *


Period Start 2018-06-20 established (approx)
  Group iTeos Therapeutics (Group)
Product Industry cancer immunotherapy (immuno-oncology, I-O)
Region Region Cambridge, MA
  Country United States (USA)
  Street 139 Main Street
  City 02142 Cambridge, MA
  Tel +1-339-217-0162
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2020-06-15)
  Currency USD
  Annual sales 4,779,000 (grant income + RnD tax credits (2019) 2019-12-31)
  Profit -22,454,000 (2019-12-31)
  Cash 21,988,000 (2019-12-31)
    * Document for »About Section«: iTeos Therapeutics S.A.. (7/28/17). "Press Release: iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region". Gosselies.
Record changed: 2023-07-10


Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top